Brainstorm Cell Therapeutics announced the final analysis of results of its Phase IIa clinical trial of NurOwn in ALS conducted at the Hadassah Medical Center in Jerusalem. The company’s stem cell therapy technology consists of transplantation of autologous mesenchymal stem cells differentiated to secrete neurotrophic factors (MSC-NTF). The small-scale trial enrolled 14 early stage ALS patients, 12 of whom were followed for 3 months or more. The company reported promising outcomes, with 92% of patients experiencing a decline in rate of disease progression based on ALS Functional Rating Score-Revised or forced vital capacity, and some patients demonstrating improvements in function. NurOwn is currently being tested in a Phase II study in the United States. Stay tuned for the results!
Click here to read more.